Kongsgaard U E, Aasen A O, Smith-Erichsen N, Bjørnskau L
Department of Anaesthesiology, Rikshospitalet, Oslo, Norway.
Eur Surg Res. 1992;24(2):119-28. doi: 10.1159/000129197.
The influence of unfractionated heparin [average molecular weight (MW) 10,000-15,000 kD] and low-molecular-weight heparin (average MW 400-600 kD) on the plasma kallikrein-kinin and the fibrinolytic system was studied in vitro. Unfractionated heparin added to plasma gave an increase in kallikrein-like activity with a corresponding decrease of prekallikrein and functional kallikrein inhibition values. Plasmin-like activity was also increased, but minor changes in plasminogen and no change in antiplasmin values occurred. The changes were less pronounced with low molecular heparin compared with unfractionated heparin. The proteolytic changes were reversed by protamine sulfate but not influenced by the protease inhibitor aprotinin. Gel filtration yielded proteolytic activities able to split the plasma kallikrein substrate S-2305 and, to a minor degree, the plasmin substrate S-2251. The proteolytic activities were not due to complex formation with alpha 2-macroglobulin. We speculate that heparin binds to prekallikrein to form a heparin-prekallikrein complex which undergoes conformational changes and displays a kallikrein-like activity with the ability to split small synthetic substrates. Whether it is capable to split natural substrates remains unresolved.
在体外研究了普通肝素(平均分子量[MW]10,000 - 15,000 kD)和低分子量肝素(平均MW 400 - 600 kD)对血浆激肽释放酶 - 激肽系统和纤维蛋白溶解系统的影响。向血浆中添加普通肝素会使激肽释放酶样活性增加,同时前激肽释放酶和功能性激肽释放酶抑制值相应降低。纤溶酶样活性也增加,但纤溶酶原仅有微小变化,抗纤溶酶值无变化。与普通肝素相比,低分子量肝素引起的变化不那么明显。这些蛋白水解变化可被硫酸鱼精蛋白逆转,但不受蛋白酶抑制剂抑肽酶影响。凝胶过滤产生了能够裂解血浆激肽释放酶底物S - 2305以及在较小程度上裂解纤溶酶底物S - 2251的蛋白水解活性。这些蛋白水解活性并非由于与α2 - 巨球蛋白形成复合物所致。我们推测肝素与前激肽释放酶结合形成肝素 - 前激肽释放酶复合物,该复合物发生构象变化并表现出具有裂解小合成底物能力的激肽释放酶样活性。它是否能够裂解天然底物仍未明确。